Gabapentin treatment for alcohol dependence a randomized clinical trial

JAMA Internal Medicine

Volumn 174, Issue 1, 2014, Pages 70-77

  Mason, Barbara J ^a   Quello, Susan ^a   Goodell, Vivian ^a   Shadan, Farhad ^b   Kyle, Mark ^b   Begovic, Adnan ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CRAVING QUESTIONNAIRE; ALCOHOL WITHDRAWAL; ALCOHOLICS ANONYMOUS; ALCOHOLISM; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPHORIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MOOD CHANGE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTPATIENT; PATIENT COMPLIANCE; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; AMINES; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84889605691     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.11950     Document Type: Article

References (45)

1. Rehm J, Mathers C, Popova S., Thavorncha-roensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223-2233.
2. Substance Abuse and Mental Health Services Administration. Results from the 2006 national survey on drug use and health: national findings. Rockville, MD: Office of Applied Studies (NSDUH Series H-32, DHHS publication No. SMA 07-4293); 2007. http://www.samhsa.gov/data/nsduh/2k6nsduh/2k6results.pdf. Accessed February 10, 2013.
3. Mark TL, Kassed CA, Vandivort-Warren R, Levit K.R., Kranzler HR Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1-3):345-349.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Press; 2013.
6. Koob GF. A role for brain stress systems in addiction. Neuron. 2008;59(1):11-34.
7. Geller A. Protracted abstinence. In: Miller NS, ed. Comprehensive Handbook of Drugs and Alcohol Addiction. New York, NY: Marcel Dekker; 1991:905-913.
8. Lowman C, Allen J, Stout RL; Relapse Research Group. Replication and extension of Marlatt's taxonomy of relapse precipitants: overview of procedures and results. Addiction. 1996;91(S51)(suppl):S51-S71.
9. Brower KJ, Aldrich MS, Hall JM Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcohol Clin Exp Res. 1998;22(8):1864-1871.
10. Foster JH, Peters TJ Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcohol Clin Exp Res. 1999;23(6):1044-1051.
11. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108-113.
12. Roberto M, Gilpin NW, O'Dell LE, et al Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci. 2008;28(22): 5762-5771.
13. Mason BJ, Light JM, Williams L.D., Drobes DJ Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009;14(1):73-83.
14. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691-1700.
15. Ghaemi SN, Katzow JJ, Desai S.P., Goodwin FK Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry. 1998;59(8):426-429.
16. Harden CL, Lazar LM, Pick L.H., et al A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia. 1999;40(8):1129-1134.
17. Karam-Hage M., Brower KJ Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry. 2000;157(1):151.
18. Lo HS, Yang CM, Lo H.G., Lee CY, Ting H, Tzang BS Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010;33(2):84-90.
19. Malcolm R, Myrick LH, Veatch L.M., Boyle E., Randall PK Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med. 2007;3(1):24-32.
20. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F., Zucker RA A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429-1438.
21. Anton RF, Myrick H, Wright T.M., et al Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709-717.
22. Sullivan JT, Sykora K, Schneiderman J., Naranjo CA, Sellers EM Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br J Addict. 1989;84(11):1353-1357.
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
24. Sobell LC, Sobell MB Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press; 1992:41-72.
25. National Institute on Alcohol Abuse and Alcoholism. The Physicians' Guide to Helping Patients With Alcohol Problems. Rockville, MD: US. Department of Health and Human Services; 1995.
26. Singleton EG, Henningfield JE, Tiffany ST Alcohol Craving Questionnaire: ACQ-Now: Background and Administration Manual. Baltimore, MD: NIDA Addiction Research Center; 1994.
27. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597.
28. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
29. Levine J, Schooler NR SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-381.
30. Mason BJ, Goodman AM Brief Intervention and Medical Compliance Procedures Therapist's Manual. New York, NY: Lipha Pharmaceuticals Inc; 1997. www.alcoholfree.info.
31. Winchell C, Rappaport BA, Roca R, Rosebraugh CJ Reanalysis of methamphetamine dependence treatment trial. CNS Neurosci Ther. 2012;18(5):367-368.
32. Falk D, Wang XQ, Liu L, et al Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res. 2010;34(12):2022-2034.
33. US Food and Drug Administration. Medical Review of Vivitrol: 21-897. Rockville, MD: US Government Printing Office; 2006.
34. Gueorguieva R, Krystal JH Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61(3):310-317.
35. Johnson BA, Ait-Daoud N, Bowden C.L., et al Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685.
36. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K., Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
37. Cohen J. Statistical Power Analysis for the Behavior Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
38. 2 tests. Biometrics. 1954;10(4):417-451.
39. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-748.
40. Norusis MJ. SPSS Statistics 17.0 Advanced Statistical Procedures Companion. Upper Saddle River, NJ: Prentice Hall Inc; 2008.
41. West BT. Analyzing longitudinal data with the linear mixed models procedure in SPSS. Eval Health Prof. 2009;32(3):207-228.
42. Neurontin (gabapentin) [package insert LAB-0106-9.0]. New York, NY: Pfizer. Revised January, 2007.
43. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36(3):497-508.
44. Sullivan JT, Swift RM, Lewis DC Benzodiazepine requirements during alcohol withdrawal syndrome: clinical implications of using a standardized withdrawal scale. J Clin Psychopharmacol. 1991;11(5):291-295.
45. Mason BJ, Crean R, Goodell V., et al A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689-1698.